The nitrogen mustard derivatives of 4-phenylbutyric acid and L-phenylalanine, called chlorambucil (Chl) and melphalan (Mel), respectively, have been incorporated into several peptide hormones, including luteinizing hormone-releasing hormone (LH-RH). The alkylating analogues of LH-RH were prepared by finking Chl, as an N-acyl moiety, to the complete amino acid sequence of agonistic and antagonistic analogues. These compounds, in particular the antagonistic analogues, showed much lower potency than their congeners carrying other acyl groups. (7), at a concentration of 0.5 nM can inhibit 0.22 nM thrombin by 50%o in less than 2 min. Consequently, the results with Chl-and Mel-containing analogues indicate the absence of a receptor nucleophile in the peptide binding site essential for biological activity of hormone receptors. Thus, we may assume that a nitrogen mustard compound such as Mel incorporated into a peptide hormone can be bound to the membrane receptors and internalized. After endocytosis, such a compound could interfere with intracellular events due to its alkylating potential.
amino]phenyl}alanine) have been incorporated as affinity labels into several peptide hormones, including bradykinin (1) , luteinizing hormone (LH)-releasing hormone (LH-RH) (2, 3) , and angiotensin II (AT-II) (4, 5) . Assuming the presence of an appropriate receptor nucleophile adjacent to the alkylating nitrogen mustard, such analogues were expected to associate with the receptor irreversibly, producing sustained blockade at a much lower dose than reversible inhibitors. However, a survey of the results obtained so far indicates that this has not occurred. Incorporation of Chl into fragments of bradykinin and related peptides (1) Affinity labels that alkylate their target molecules are known to bring about irreversible inhibition in a fast reaction, near to stoichiometry. For example, D-Phe-Pro-Arg-CH2Cl, a thrombin inhibitor of this type (7), at a concentration of 0.5 nM can inhibit 0.22 nM thrombin by 50%o in less than 2 min. Consequently, the results with Chl-and Mel-containing analogues indicate the absence of a receptor nucleophile in the peptide binding site essential for biological activity of hormone receptors. Thus, we may assume that a nitrogen mustard compound such as Mel incorporated into a peptide hormone can be bound to the membrane receptors and internalized. After endocytosis, such a compound could interfere with intracellular events due to its alkylating potential.
To study this hypothesis, Mel-containing LH-RH analogues with high agonistic or antagonistic activities were synthesized on the basis of the known structure-activity relationships found among LH-RH analogues (8) . (10) suspended in acetonitrile containing triethylamine was acylated with di-tert-butyl dicarbonate and then reacted with pentachlorophenyl trichloroacetate (11) .
MATERIALS AND METHODS
Peptides. D-Mel6-containing LH-RH analogues were obtained by coupling of appropriate pentapeptide fragments consisting of residues 1-5 and 6-10. The intermediate pentapeptides 1-5 and the tetrapeptide amide (residues [7] [8] [9] [10] portion of the C-terminal fragments 6-10 were prepared by standard manual solid-phase synthesis (12) mediate peptides 1-5, the C-terminal (fifth residues) [BocTyr(CI2Bzl) and Boc-Arg(Tos)] were anchored to the chloromethyl resin by the KF method (13) . Coupling was achieved with preformed 1-hydroxybenzotriazole esters prepared as follows: 2 mmol of protected amino acid in 1 ml of dimethylformamide plus 2 ml of dichloromethane was reacted with 2 mmol of 1-hydroxybenzotriazole and 2.2 mmol of N,N'-diisopropylcarbodiimide at 0°C for 15 min and then added to the resin with four 2-ml dichloromethane rinses. The mixture was shaken for 90-120 min. Deblocking was performed with trifluoroacetic acid/dichloromethane (1:1). Acetylation of the N terminus was done with a 10-fold excess of acetic anhydride in the presence of imidazole. Peptideresins were treated with HF (15 ml/g of peptide-resin) at 0°C for 45 min in the presence of 10% anisole. The HF was removed under vacuum, and the residue was triturated with anhydrous diethyl ether and filtered. Peptides were extracted from the resin with aqueous 50% acetic acid and lyophilized to yield crude peptides. To obtain compounds D-Mel-LeuArg-Pro-Gly-NH2 (Cl) and D-Mel-Leu-Arg-Pro-D-Ala-NH2 (C2), the corresponding tetrapeptide amide was acylated with Boc-D-Mel-OPhCl5. The intermediate pentapeptides were condensed by the N,N'-dicyclohexylcarbodiimide/1-hydroxytriazole method (13) in dimethylformamide at 00 for about 24 hr. The desired peptides were isolated from the reaction mixtures by HPLC.
HPLC. Purification of crude products was performed on a Beckman HPLC system (type 142) using a Dynamax macro column (21.2 x 250 mm) packed with spherical C18 silica gel (300-A pore size, 12-gm particle size). Elution was with solvent systems consisting of components A and B as follows. System i: A, 0.1% trifluoroacetic acid; B, 0.1% trifluoroacetic acid in aqueous 70% acetonitrile (gradient elution). System ii: A, 0.2% acetic acid; B, 0.2% acetic acid in aqueous 70% acetonitrile (gradient elution). System ii was used for the purification of D-Mel-containing peptides.
Analytical HPLC was run on a Hewlett-Packard model HP-1090 liquid chromatograph using a 4.6 x 250-mm WPorex 5-,.m C18 column (Phenomenex, Rancho Palos Verdes, CA). Elution was at 1.2 ml/min with solvent system i (linear gradient mode).
Amino Acid Analysis. Analyses were performed with a Beckman 6300 amino acid analyzer. Samples were hydrolyzed at 110°C for 20 hr in evacuated sealed tubes containing 4 M methanesulfonic acid and 0.2% 3-(2-aminoethyl)indole.
Agonist/Antagonist Activity. LH-releasing and LH-RHinhibiting activities were assayed in a dispersed rat pituitary cell superfusion system (14) . For agonist response the peptide was infused for 3 min at various concentrations (1 pM-1 nM); the LH-releasing effect of the peptide was related to that of 3 nM LH-RH. To test the LH-RH antagonistic effect the peptide was perfused for 9 min (3 ml of perfusate) at 3 nM. Immediately after that, a mixture containing 3 nM peptide and 3 nM LH-RH was administered for 3 min (12 ml; 0-min response). The kinetics of the effect of the peptide were analyzed by infusion of 3 nM LH-RH for 3 min (1 ml) four times at 30-min intervals (30, 60, 90, 120 min). LH content of the 1-ml fractions collected was determined by radioimmunoassay using National Institute of Diabetes and Digestive and Kidney Diseases kits.
An in vivo antiovulatory assay was carried out in 4-day cycling rats as described (15 (16) (17) (18) . RESULTS D-Mel6-containing LH-RH analogues I-IV were synthesized by coupling of appropriate N-terminal (N1-N4) and Cterminal (Cl, C2) pentapeptide fragments ( Table 1 ). The intermediate peptides N1-N4 and the tetrapeptide amide (residues 7-10) portion of C1 and C2 were prepared by the solid-phase method (12) . Acylation ofthe tetrapeptide amides with Boc-D-Mel-OPhCl5 followed by deblocking produced intermediates C1 and C2. In spite of the use of the dicyclohexylcarbodiimide/1-hydroxytriazole method (13), some racemization did occur during the coupling of the pentapeptide fragments, in particular in the synthesis of analogues HI and IV containing the Arg5 residue. Due to the known instability of D-Mel-peptides (4), they were kept in solution for the shortest possible period of time. After purification by preparative HPLC, the purity of isolated peptides was judged to be >90% in analytical HPLC. Upon standing in solution, two faster moving decomposition products were formed from each compound. For solvent system i with a gradient of 40-80% B in 40 min, retention times for the desired peptides and their decomposition products (given in parentheses) were as follows: I, 11.4 (4.1, 8.6) min; II, 25.2 (7.2, 14.3) min; m, 27.1 (6.5, 14.9) min; IV, 19.2 (5.0, 11.4) min.
Hormonal activities of the peptides in vitro were assayed in a dispersed rat pituitary superfusion system (Table 2) . Agonistic analogue I, [D-Mel6]LH-RH, showed LH-releasing potency about 130 times higher than LH-RH and about 1.4 times greater than superagonist [D-Trp6]LH-RH. Of the antagonistic analogues, IV exerted high and long-lasting inhibitory action on the LH-RH-mediated LH release, whereas II and Ill showed only moderate activity.
As indicated in Table 3 , the in vivo antiovulatory activity of analogue IV was very high. A much lower potency was found for HI, and II was inactive. (Table  5 ). Under such conditions antagonistic analogue IV showed the highest affinities for the receptors. The lowest affinities of analogues I and II were found when their own labeled congeners were used.
Affinities of the D-Mel6 analogues I-IV and [D-

DISCUSSION
The synthesis of Mel-containing analogues of LH-RH was based on the fact that incorporation of a hydrophobic residue into the LH-RH sequence often yields an active analogue. It has long been known (8) demonstrates that D-Mel can be used as a very favorable hydrophobic D amino acid residue that produces great increase in activity when it is substituted in LH-RH analogues.
The intensity and duration of the LH-RH antagonistic activity of analogues il-lV were also examined in the superfusion assay ( Table 2 ). The intensity of the instant antagonistic activity was determined by exposure to 3 nM LH-RH for 3 min in the presence of the analogue after preincubation with it for 9 min. The kinetics ofthe antagonistic activity were analyzed by exposing cells preincubated with the antagonists to 3 nM LH-RH four times for 3 min at 30-min intervals. The instant inhibitory effects obtained for compounds 11, 11 , and IV were 66%, 24%, and 88%, respectively, indicating that IV, with D-Pal(3)3, is a powerful inhibitor, whereas its D-Trp3 congener, Il, is a rather poor inhibitor. More than two-thirds of the higher instant inhibitory potency of compounds H and IV, and all of the low potency of compound Il, could still be detected 2 hr after the infusion of the antagonists had been stopped. We may conclude from these findings that once a D-Mel6 antagonist is bound to the receptor, it remains attached for a long time. With respect to the initial binding of these analogues, the D-Nal(2)1,D-Pal(3)3 combination is the best, and Prol,D-Trp3 is more favorable than D-Nal(2)1,DTrp3, the most hydrophobic combination of the three.
Compound IV, which was the most active analogue in vitro, also exerted the highest potency in vivo (Table 3) . Interestingly, compound HI, the least active analogue in vitro, caused 100% blockade of ovulation at a dose of 10 ,ug, whereas H did not exert antiovulatory activity in vivo at this dose although it was twice as potent as analogue m in the superfusion assay.
Affinity constants for binding of analogues I-IV and [DTrp6]LH-RH to membrane receptors in the pituitaries of male rats are given in Table 4 These properties can be easily explained by their structures: each contained the most favored substitution, i.e., a highly hydrophobic D amino acid residue in the sixth position. Among the antagonistic analogues H-IV, however, much more complex structure-activity relationships seemed to exist. While IV showed high affinity for the pituitary receptors and, in accordance with this, exerted strong inhibitory action both in vitro and in vivo, the closely related analogue m had 600 times lower affinity although it was only 3-5 times less active in the bioassays. Even lower affinity was found for H, which was somewhat more active in vitro than m but was Table 3 These constants for antagonist IV were 0.7 nM-1 and 1.68 nM-1, respectively.
Alterations of the affinity pattern of the peptides discussed above suggest that rat pituitary and human breast cancer cell membranes contain structurally related peptide receptors, whereas the receptors found on the membranes of human prostate cancer and rat Dunning tumor may differ from each other as well as from the pituitary breast cancer receptors. D-Mel6-containing 1251-labeled analogues of LH-RH can also be displaced by their alkylating (I, II, and IV) and nonalkylating ([D-Trp6]LH-RH) congeners (Table 5 ). These findings suggest that the D-Mel6-containing analogues of LH-RH bind to the receptors reversibly and that no alkylation of the LH-RH receptors occurs.
Two of these Mel-containing analogues, agonist I (SB-05) and antagonist IV (SB-86), were evaluated in vitro for cytotoxicity. We were able to demonstrate significant cytotoxic activity (inhibition of 
